PDGFRA and gastrointestinal stromal tumor: Avapritinib and ripretinib were approved in 2020 for GIST patients harbouring PDGFRA exon 18 mutation and advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib, respectively [16].